ISSN(print)：2218-676X
影响因子： 1.7
刊出率：
最近未读
0
Translational Cancer Research (Transl Cancer Res, TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; https://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in PubMed/PubMed Central and Web of Science [Science Citation Index Expanded (SCIE)]. Its latest impact factor (2023 citation year) is 1.5.
TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer, results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. It is published bimonthly (Jun. 2012 - Aug. 2019), monthly (Sep. 2019 -) and openly distributed worldwide.
The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. (For more details: https://tcr.amegroups.org/about)
